Brit J Haematol: new drugs significantly improve the survival of patients with blood cancer

June 26, 2018 / bioin / mantle cell lymphoma (MCL) treatment status has changed dramatically in recent years The clinical experiment results show that the survival rate of patients has been significantly improved However, there are few clinical results about the public use of these drugs, so researchers don't know whether the drugs with clinical efficacy also play an equally excellent role in the actual use process Image source: Wikimedia Commons Based on this, scientists from UK York University and other units recently investigated the first-line and relapsed / refractory (RR) disease management of 335 patients diagnosed with MCL between 2004 and 2015, and collected their demographic, diagnosis and prognostic factor related information The relevant research results were published in British Journal of recent years In haematology, it is entitled "impact of new therapies for mantle cell lymphama in the real world setting: a report from the UK's haematological anomaly research network (hmrn)." The researchers observed significant improvements in treatment and survival: for example, in 11 years, the use of rituximab as a first-line immunotherapy increased from 32% to 86%, and the median survival increased from 2 years in 2004-2011 to 3.5 years in 2012-2015 The results of RR treatment also improved significantly: from 8 months in 2004-2011 to 16.8 months in 2012-2015, which was consistent with the introduction of bendamoxetine, irutini and other drugs What's more encouraging is that the prognosis of patients of all ages has improved significantly, and the 1-year overall survival rate of patients with RR disease status over 70 years old has almost doubled The results of this study show that it is very important to monitor the changes in clinical outcomes caused by changes in new drugs or treatment methods Reference: Alexandra Smith et al Impact of new therapies for mantle cell lymphama in the real world setting: a report from the UK's haematological anomaly research network (hmrn), British Journal of Haematology (2018) Doi: 10.1111/bjh.15170